choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Viread

Viread Newsletter
  • Two-Drug Regimen Matches Three-Drug Regimen in HIV Care 04 Nov 2025 09:35 GMT

    … Among treatment-naive people with HIV infection, the two-drug … the three-drug regimen DTG plus tenofovir alafenamide… this randomized clinical trial suggest no differences … receiving financial support from pharmaceutical companies, including Gilead …

  • Revealed: PS, retired director culpable in drugs shortage – ACC 02 Nov 2025 21:26 GMT

    … one million units of the drug Tenofovir/Lamivudine/Dolutegravir … between government and the pharmaceutical suppliers was a civil … the agreement itself provided remedies such as penalties or … the public, stating that the shortage of drugs ‘continues to …

  • <![CDATA[Treatment Switching in Virologically Suppressed Patients With HIV]]> 02 Nov 2025 04:41 GMT

    … to avoid daily pills. Overall, regimen … drug regimen bictegravir/emtricitabine/tenofovir alafenamide in treatment … ingredients in osteoporosis medications. Multivalent cations can … REPRIEVE trial (NCT02344290) showed that initiating statins in …

  • <![CDATA[Meeting the Needs of Patients With HIV: Virologic Suppression and the Expanding Treatment Landscape]]> 02 Nov 2025 04:41 GMT

    trial started treatment-naïve participants on a 3-drug oral HIV treatment … ’ treatment by reducing the number of pills or pill frequency … care teams, and pharmaceutical research and development. Conclusion … 2-drug regimen vs continuing a tenofovir alafenamide-based …

  • Top 20 Drugs Heading for the Patent Cliff, 2026-2029 01 Nov 2025 21:10 GMT

    … on billion-dollar-plus “blockbuster” drugs generating approximately $230 billion in … or companies that market the treatment, the year of initial U … ’ Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide; $2.503 billion).       See …

  • Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results 06 Nov 2025 13:30 GMT

    … Aligos”), a clinical stage biotechnology company focused on improving … monotherapy compared with tenofovir disoproxil fumarate in … (RAs) for the treatment of obesity. Recently generated … designing and conducting clinical trials, the regulatory approval …

  • One-Pill Bictegravir Can Control Resistant HIV Infection 28 Oct 2025 10:42 GMT

    … /emtricitabine/tenofovir alafenamide demonstrated sustained virologic … one or more antiretroviral drugs. Clinical data were … stable. Five patients discontinued treatment during follow-up: … interactions, toxicity and pill burden in patients harbouring …

  • Hepatitis B reactivation is rare after switching from tenofovir, two European studies show 24 Oct 2025 09:55 GMT

    … Switching to a tenofovir-sparing, two-drug HIV treatment regimen poses a … switching; both reverted to treatment with tenofovir alafenamide, emtricitabine and bictegravir … HBV reactivation before resuming tenofovir-containing treatment. “I really think …

  • 2024 First Generic Drug Approvals 23 Oct 2025 18:33 GMT

    … USP BWXT Medical Ltd AdreView … treatment of erectile dysfunction 38 215570 Palbociclib Tablets Synthon Pharmaceuticalstreatment of adults with carcinoid syndrome 30 214053 Emtricitabine and Tenofovir … 18 mg Indoco Remedies Limited Lucemyra (Lofexidine …

  • HBV Reactivation Risk Low After Tenofovir Cessation in HIV 22 Oct 2025 14:25 GMT

    … growing adoption of dual-drug and long-acting injectable … do not contain the HBV treatment tenofovir. HBV Reactivation Below Limits … infectious diseases/HIV medicine at the Royal Free … individuals to tenofovir-sparing regimens when it reduces pill burden, …

Satisfied with the content?

Continue to create your account.